UniQuest

The ultra-rare disease specialist Ultragenyx is approaching several important catalysts this year, including US Food and Drug Administration action on UX111 – the firm’s first gene therapy, which targ

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. ProQR Ge

Biopharmaceutical start-up companies – firms founded four years ago or less – raised fewer dollars during the third quarter than during the prior quarter despite Roivant Sciences GMBH 's massive $1

Below is Scrip’s monthly roundup, compiled by Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. For Phil Robilotto, v